All Posts: mind
-
Researchers Report First Therapy Appearing to Reverse Decline in Parkinson’s
OCTOBER 17, 2015 – An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC). The drug, nilotinib (known as Tasigna® by Novartis) also led to statistically significant and encouraging changes in toxic […]
Category: GUMC Stories
-
Cancer Drug Improved Cognition and Motor Skills in Small Parkinson’s Clinical Trial
CHICAGO (Oct. 17, 2015) — An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University Medical Center (GUMC) in Washington. In addition, the drug, nilotinib (Tasigna® by Novartis), led to statistically significant […]
Category: News Release
-
Resveratrol Impacts Alzheimer’s Disease Biomarker
WASHINGTON — The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol.
Category: News Release
-
Patients Drive Support Of Parkinson’s Fellowship Program
March 2, 2015 — Twelve years ago, Rick Schena, a United Airlines pilot, felt something amiss in the body he has always been so in tune with — the onset of tremors, some rigidity, and issues with processing vision. Six years ago he was diagnosed with Parkinson’s. This was devastating to the speed junkie who […]
Category: GUMC Stories
-
Researcher Debunks Alzheimer's Prevailing Development Theory
(October 31, 2014) – New research that dramatically alters the prevailing theory of how Alzheimer’s disease develops has been published online today by Georgetown researchers in the journal Molecular Neurodegeneration. The research also helps explains why some people with plaque buildup in their brains don’t develop dementia, and shows the potential of a cancer drug […]
Category: GUMC Stories
-
Tau, Not Amyloid-beta, Triggers Neuronal Death Process in Alzheimer’s
WASHINGTON (Oct. 31, 2014) — New research points to malfunctioning tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer’s disease. The finding, which dramatically alters the prevailing theory of Alzheimer’s development, also explains why some people with plaque build-up in their brains don’t have dementia. The […]
Category: News Release
-
Cancer Drug Prevents Build-up of Toxic Brain Protein
WASHINGTON (May 10, 2013) — Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson’s disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects. They say their study, published […]
Category: News Release